Zhao L.,Beijing Hospital of the Ministry of Health
Zhonghua nei ke za zhi [Chinese journal of internal medicine] | Year: 2011
To study the efficacy and safety of combined therapy of compound azintamid and domperidone in functional dyspepsia. A randomised, double-blind, placebo-controlled trial. Two hundred and eight patients with functional dyspepsia were randomly grouped into group A (experimental group, 102 cases) and group B (control group, 106 cases). The patients in the group A were given 2 tablets of compound azintamid 3 times a day in addition to domperidone 10 mg 3 times per day for four weeks. The patients in the group B were only given domperidone 10 mg 3 times per day for 4 weeks. The therapeutic efficacy was evaluated by modified Severity of Dyspepsia Assessment (mSODA) and Global Patient Assessment (GPA). Subscore in mSODA: the change of bloating/pain intensity score in group A is -12.35 ± 5.48 while group B is -10.52 ± 4.65 (P = 0.009), the change of non-bloating/pain symptoms score in group A is -5.75 ± 3.31 while group B is -4.86 ± 2.65 (P = 0.033), and the change of satisfaction score in group A is 7.09 ± 3.78 while group B is 5.62 ± 3.54 (P = 0.004). The response rate in group A is 89.2% which is significantly higher than 76.4% in group B (P = 0.015). Other symptoms for response assessment included loss of appetite, early satiety, fullness after meal, diarrhea. No severe side-effect was found in both groups. Combined therapy of compound azintamid and domperidone may lead to bigger improvement in overall efficacy and health related quality of life in patients with functional dyspepsia than use of motility medicine alone. Potential mechanisms that may account for the efficacy of compound azintamide in functional dyspepsia include modulation of visceral sensitivity and/or gastrointestinal motility.
Wang F.,Beijing Hospital of the Ministry of Health
Chinese Journal of New Drugs | Year: 2011
Many clinical trials showed that n-3 polyunsaturated fatty acids (n-3 PUFAs) have protective effects for patients with coronary heart disease, dyslipidemia and heart failure. And n-3 PUFAs are recommended for secondary prevention in patients after myocardial infarction and for the treatment of hypertriglyceridaemia. However, there are some concerns in their clinical application, such as drug safety, compositions, dosages and so on. With further research, n-3 PUFA drugs will have broader prospects for development.
Wang L.,CAS Institute of Biophysics |
Wu J.,Salk Institute for Biological Studies |
Fang W.,Beijing Hospital of the Ministry of Health |
Liu G.-H.,CAS Institute of Biophysics |
And 3 more authors.
Cell Research | Year: 2015
The CRISPR/Cas system has proven to be a powerful gene editing tool both in vitro and in vivo. A recent flurry of studies of in vivo gene editing using the CRISPR/Cas system bring bright prospects in creating animal models and targeted gene therapy of human genetic diseases. © 2015 IBCB, SIBS, CAS All rights reserved.
Zhang Y.,Peking Union Medical College |
Li M.,Beijing Hospital of the Ministry of Health |
Kang R.-X.,Peking Union Medical College |
Shi J.-G.,Peking Union Medical College |
And 2 more authors.
Pharmacology Biochemistry and Behavior | Year: 2012
The rhizomes of Gastrodia elata have been used for the treatment of insomnia in oriental countries. N6-(4-hydroxybenzyl) adenine riboside (NHBA) was originally isolated from G. elata. For the first time we report a detailed study on the effects and mechanisms of NHBA on its sedative and hypnotic activity. Adenosine, an endogenous sleep factor, regulates sleep-wake cycle via interacting with adenosine A1/A2A receptors. Using radioligand binding studies and cAMP accumulation assays, our results show that NHBA may be a functional ligand for the adenosine A1 and A 2A receptors. NHBA significantly decreases spontaneous locomotor activity and potentiates the hypnotic effect of sodium pentobarbital in mice. Sleep architecture analyses reveal that NHBA significantly decreases wakefulness time and increases NREM sleep times. However, NHBA does not affect the amount of REM sleep. Pretreatment with the adenosine A1 receptor antagonist DPCPX or the A2A receptor antagonist SCH 58261 significantly reverses the increase in sleeping time induced by NHBA in sodium pentobarbital treated mice. Immunohistochemical studies show that NHBA increases c-Fos expression in GABAergic neurons of the ventrolateral preoptic area (VLPO), which suggests that NHBA activates the sleep center in the anterior hypothalamus. Altogether, these results indicate that NHBA produces significant sedative and hypnotic effects. Such effects might be mediated by the activation of adenosine A 1/A2A receptors and stimulation of the sleep center VLPO. © 2012 Elsevier Inc.
Li C.,Beijing Hospital of the Ministry of Health |
Chen M.,Beijing Hospital of the Ministry of Health |
Li S.,Beijing Hospital of the Ministry of Health |
Zhao X.,Peking University |
And 3 more authors.
Acta Radiologica | Year: 2014
Background: Previous studies have shown that the diagnostic accuracy for prostate cancer improved with diffusion tensor imaging (DTI) or quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) only. However, the efficacy of combined DTI and quantitative DCE-MRI in detecting prostate cancer at 3.0 T is still indeterminate. Purpose: To investigate the utility of diffusion tensor imaging (DTI), quantitative DCE-MRI, and the two techniques combined at 3.0 T in detecting prostate cancer of the peripheral zone (PZ). Material and Methods: DTI and DCE-MRI of 33 patients was acquired prior to prostate biopsy. Regions of interest (ROIs) were drawn according to biopsy zones which were apex, mid-gland, and base on each side of the PZ. Apparent diffusion coefficient (ADC), fractional anisotropy (FA), volume transfer constant (K trans), and rate constant (kep) values of cancerous sextants and non-cancerous sextants in PZ were calculated. Logistic regression models were generated for DTI, DCE-MRI, and DTI-DCE-MRI. Receiver-operating characteristic (ROC) curves were used to compare the ability of these models to differentiate cancerous sextants from non-cancerous sextants of PZ. Results: There were significant differences in the ADC, FA, Ktrans, and k ep values between cancerous sextants and noncancerous sextants in PZ (P>0.0001, P>0.0001, P>0.0001, and P>0.0001, respectively). The area under curve (AUC) for DTI-DCE-MRI was significantly greater than that for either DTI (0.93 vs. 0.86, P=0.0017) or DCE-MRI (0.93 vs. 0.84, P=0.0034) alone. Conclusion: The combination of DTI and quantitative DCE-MRI has better diagnostic performance in detecting prostate cancer of the PZ than either technique alone. © The Foundation Acta Radiologica 2013.